retatrutide dosing phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Phase III retatrutide study demonstrates

4 Therefore, the use of a GLP-1 receptor agonist (exenatide, liraglutide) can be used as monotherapy or dual therapy in those with an A1C of 6.5% to 7.5%

That may include weight loss, improved insulin sensitivity, reduced visceral fat, better cardiometabolic markers, lower inflammatory burden, improved mobility, and greater capacity to exercise

Retatrutide is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems

The opportunity could be massive

Reta is currently in early-stage clinical trials and is not approved for human or veterinary use

Three times weekly dosing on a Monday, Wednesday, Friday schedule reduces peaks by 35% with a peak-to-trough ratio of 1.6